{
      "Rank": 1,
      "Acronym": [
            "DREAM HF-1"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Participants randomly assigned to treatment will undergo a single index cardiac catheterization involving transendocardial delivery of rexlemestrocel-L into the myocardium at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.",
            "Participants randomly assigned to control treatment will undergo a single cardiac catheterization involving a scripted sham cardiac mapping and cell delivery procedure at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results."
      ],
      "ArmGroupInterventionName": [
            "Biological: Allogeneic Mesenchymal Precursor Cells (MPCs)",
            "Other: Sham Comparator"
      ],
      "ArmGroupLabel": [
            "Allogeneic Mesenchymal Precursor Cells",
            "Control Treatment"
      ],
      "ArmGroupType": [
            "Experimental",
            "Sham Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02032004"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The primary objective of this study is to determine whether transendocardial delivery of allogeneic human bone marrow-derived mesenchymal precursor cells (MPCs [rexlemestrocel-L]) is effective in the treatment of chronic heart failure (HF) due to left ventricular (LV) systolic dysfunction."
      ],
      "BriefTitle": [
            "Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure."
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "May 29, 2020"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Chronic Heart Failure"
      ],
      "ConditionAncestorId": [
            "D000006331",
            "D000002318"
      ],
      "ConditionAncestorTerm": [
            "Heart Diseases",
            "Cardiovascular Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC14",
            "All",
            "BC23",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Heart and Blood Diseases",
            "All Conditions",
            "Symptoms and General Pathology",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Heart Failure"
      ],
      "ConditionBrowseLeafId": [
            "M8573",
            "M9695",
            "M26736",
            "M8571",
            "T1303"
      ],
      "ConditionBrowseLeafName": [
            "Heart Failure",
            "Ischemia",
            "Systolic Murmurs",
            "Heart Diseases",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000006333"
      ],
      "ConditionMeshTerm": [
            "Heart Failure"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Triple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "The purpose of this study is to evaluate the efficacy and safety of a single transendocardial delivery in the cardiac catheterization laboratory of human bone marrow-derived allogeneic MPCs (rexlemestrocel-L) for improvement in clinical outcomes (heart failure major adverse cardiac events [HF-MACE]), preventing further adverse cardiac remodeling (left ventricular end systolic volume [LVESV] and left ventricular end-diastolic volume [LVEDV]), and increasing exercise capacity (six-minute walking test [6MWT]) in patients with chronic HF due to LV systolic dysfunction of either ischemic or nonischemic etiology who have received optimal medical/revascularization therapy."
      ],
      "DispFirstPostDate": [
            "May 25, 2021"
      ],
      "DispFirstPostDateType": [
            "Actual"
      ],
      "DispFirstSubmitDate": [
            "May 21, 2021"
      ],
      "DispFirstSubmitQCDate": [
            "May 21, 2021"
      ],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nThe patient is 18 to 80 years of age, inclusive; both men and women will be enrolled.\nThe patient has a diagnosis of chronic HF of ischemic or nonischemic etiology for at least 6 months\nThe patient is on stable, optimally tolerated dosages of HF therapies including beta-blockers (approved for country-specific usage), angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and/or aldosterone antagonists, without change in dose for at least 1 month before study intervention\nThe patient is on a stable, outpatient, oral diuretic dosing regimen in which the patient remains clinically stable during screening.\nOther Criteria apply, please contact the investigator\n\nExclusion Criteria:\n\nThe patient has NYHA Functional Class I or Functional Class IV symptoms.\nOther Criteria apply, please contact the investigator"
      ],
      "EnrollmentCount": [
            "566"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "Yes"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Allogeneic Mesenchymal Precursor Cells",
            "Control Treatment"
      ],
      "InterventionBrowseBranchAbbrev": [
            "All"
      ],
      "InterventionBrowseBranchName": [
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M9336",
            "M3377"
      ],
      "InterventionBrowseLeafName": [
            "Immunoglobulins",
            "Antibodies"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Rexlemestrocel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo, and cryopreserved",
            "The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Allogeneic Mesenchymal Precursor Cells (MPCs)",
            "Sham Comparator"
      ],
      "InterventionOtherName": [
            "MPCs",
            "rexlemestrocel-L"
      ],
      "InterventionType": [
            "Biological",
            "Other"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Chronic Heart Failure",
            "CHF",
            "Left Ventricular Systolic Dysfunction",
            "Ischemic Heart Failure",
            "Nonischemic Heart Failure",
            "Stem Cells",
            "Allogeneic Mesenchymal Precursor Cells"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "January 10, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "January 5, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Mesoblast, Inc."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Birmingham",
            "Birmingham",
            "Gilbert",
            "Mesa",
            "Phoenix",
            "Tucson",
            "La Jolla",
            "La Jolla",
            "Los Angeles",
            "Los Angeles",
            "Orange",
            "Oxnard",
            "Stanford",
            "Boynton Beach",
            "Clearwater",
            "Gainesville",
            "Jacksonville",
            "Miami",
            "Orlando",
            "Tampa",
            "Atlanta",
            "Augusta",
            "Chicago",
            "Iowa City",
            "Lexington",
            "Louisville",
            "New Orleans",
            "Boston",
            "Saginaw",
            "Minneapolis",
            "Rochester",
            "Las Vegas",
            "Newark",
            "New York",
            "Charlotte",
            "Durham",
            "Cincinnati",
            "Cincinnati",
            "Cleveland",
            "Columbus",
            "Allentown",
            "Philadelphia",
            "Philadelphia",
            "Philadelphia",
            "Pittsburgh",
            "Germantown",
            "Austin",
            "Dallas",
            "Houston",
            "Houston",
            "Salt Lake City",
            "Seattle",
            "Madison",
            "Milwaukee",
            "Milwaukee",
            "Wausau",
            "Edmonton",
            "Victoria",
            "Toronto"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "Canada",
            "Canada",
            "Canada"
      ],
      "LocationFacility": [
            "Mesoblast Investigational Site 10757 - Cardiology, P.C.",
            "Mesoblast Investigational Site 13262 - University of Alabama at Birmingham Hospital",
            "Mesoblast Investigational Site 10779 - Mercy Gilbert Medical Center",
            "Mesoblast Investigational Site 10786 - Cardiovascular Associates of Mesa",
            "Mesoblast Investigational Site 10756 - Mayo Clinic",
            "Mesoblast Investigational Site 13023 - University of Arizona Medical Center",
            "Mesoblast Investigational Site 10754 - University of California, San Diego",
            "Mesoblast Investigational Site 10759 - Scripps Clinic",
            "Mesoblast Investigational Site 13265 - University of California, Los Angeles",
            "Mesoblast Investigational Site 10775 - Cedars-Sinai Medical Care Foundation",
            "Mesoblast Investigational Site 10778 - Orange County Cardiology",
            "Mesoblast Investigational Site 13031 - St. John's Regional Medical Center",
            "Mesoblast Investigational Site 13275 - Stanford University Hospital",
            "Mesoblast Investigational Site 13267 - Bethesda Heart Hospital",
            "Mesoblast Investigational Site 10780 - Morton Plant Hospital",
            "Mesoblast Investigational Site 10760 - Shands Hospital, University of Florida",
            "Mesoblast Investigational Site 13273 - University of Florida Health",
            "Mesoblast Investigational Site 10768 - University of Miami",
            "Mesoblast Investigational Site 13280",
            "Mesoblast Investigational Site 13264 - Florida Hospital Pepin Heart Institute",
            "Mesoblast Investigational Site 13027 - Emory University School of Medicine",
            "Mesoblast Investigational Site 10765 - Georgia Regents University",
            "Mesoblast Investigational Site 10772 - University Cardiologist, Rush University Medical Center",
            "Mesoblast Investigational Site 13030 - University of Iowa",
            "Mesoblast Investigational Site 10783 - Gill Heart Institute, University of Kentucky",
            "Mesoblast Investigational Site 13022 - University of Louisville",
            "Mesoblast Investigational Site 13266",
            "Mesoblast Investigational Site 10782",
            "Mesoblast Investigational Site 10766 - Michigan Cardiovascular Institute",
            "Mesoblast Investigational Site 10762 - Minneapolis Heart Institute",
            "Mesoblast Investigational Site 10761 - Mayo Clinic",
            "Mesoblast Investigational Site 13281",
            "Mesoblast Investigational Site 13263 - RWJ Barnabas Heart Center",
            "Mesoblast Investigational Site 10776 - Columbia University Medical Center",
            "Mesoblast Investigational Site 13026 - Sanger Heart and Vascular Institute, Carolinas Healthcare System",
            "Mesoblast Investigational Site 10781 - Duke University",
            "Mesoblast Investigational Site 10758 - The Christ Hospital",
            "Mesoblast Investigational Site 10770 - University of Cincinnati",
            "Mesoblast Investigational Site 10773",
            "Mesoblast Investigational Site 13278 - OhioHealth Research Institute",
            "Mesoblast Investigational Site 10785 - Lehigh Valley Hospital",
            "Mesoblast Investigational Site 13261 - University of Pennsylvania",
            "Mesoblast Investigational Site 10767 - Temple University Hospital",
            "Mesoblast Investigational Site 13277",
            "Mesoblast Investigational Site 10774 - University of Pittsburgh",
            "Mesoblast Investigational Site 10777 - Stern Cardiovascular Foundation",
            "Mesoblast Investigational Site 13024 - Austin Heart, PLLC",
            "Mesoblast Investigational Site 13274 - Soltero CV Research Center, Baylor Scott & White Research Institute",
            "Mesoblast Investigational Site 10755 - Texas Heart Institute",
            "Mesoblast Investigational Site 13268 - Houston Methodist Hospital",
            "Mesoblast Investigational Site 10763 - University Hospital",
            "Mesoblast Investigational Site 10771 - Heart & Vascular Research, Swedish Medical Center",
            "Mesoblast Investigational Site 10764 - University of Wisconsin",
            "Mesoblast Investigational Site 10769 - Aurora Healthcare",
            "Mesoblast Investigational Site 13279",
            "Mesoblast Investigational Site 10789 - Aspirus Research Institute",
            "Mesoblast Investigational Site 11027",
            "Mesoblast Investigational Site 11024 - Victoria Heart Institute Foundation",
            "Mesoblast Investigational Site 11025 - St. Michael's Hospital"
      ],
      "LocationState": [
            "Alabama",
            "Alabama",
            "Arizona",
            "Arizona",
            "Arizona",
            "Arizona",
            "California",
            "California",
            "California",
            "California",
            "California",
            "California",
            "California",
            "Florida",
            "Florida",
            "Florida",
            "Florida",
            "Florida",
            "Florida",
            "Florida",
            "Georgia",
            "Georgia",
            "Illinois",
            "Iowa",
            "Kentucky",
            "Kentucky",
            "Louisiana",
            "Massachusetts",
            "Michigan",
            "Minnesota",
            "Minnesota",
            "Nevada",
            "New Jersey",
            "New York",
            "North Carolina",
            "North Carolina",
            "Ohio",
            "Ohio",
            "Ohio",
            "Ohio",
            "Pennsylvania",
            "Pennsylvania",
            "Pennsylvania",
            "Pennsylvania",
            "Pennsylvania",
            "Tennessee",
            "Texas",
            "Texas",
            "Texas",
            "Texas",
            "Utah",
            "Washington",
            "Wisconsin",
            "Wisconsin",
            "Wisconsin",
            "Wisconsin",
            "Alberta",
            "British Columbia",
            "Ontario"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "35211",
            "35233",
            "85297",
            "85206",
            "85054",
            "85724",
            "92037",
            "92037",
            "90045",
            "90211",
            "92868",
            "93030",
            "94305",
            "33435",
            "33756",
            "32610",
            "32209",
            "33215",
            "33613",
            "30322",
            "30912",
            "60612",
            "52242",
            "40536",
            "40202",
            "48602",
            "55407",
            "55905",
            "07112",
            "10032",
            "28203",
            "27710",
            "45219",
            "45267",
            "43214",
            "18103",
            "19104",
            "19140",
            "15213",
            "38125",
            "78756",
            "75226",
            "77030",
            "77030",
            "84132",
            "98122",
            "53792",
            "53215",
            "54401",
            "V8R 4R2",
            "M5B 1W8"
      ],
      "MaximumAge": [
            "80 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Mesoblast, Ltd."
      ],
      "OrgStudyId": [
            "MSB-MPC-CHF001"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [
            "Pharmacodynamics Measures (N-terminal (NT)-pro hormone BNP [NT-proBNP] and high-sensitivity C-reactive protein [hs-CRP])",
            "Pharmacogenomics (PGx) Analysis",
            "Immunogenicity Measures (panel reactive antibodies, donor specific antibody, if panel-reactive antibody (PRA) test is positive, antibodies against bovine and murine products)"
      ],
      "OtherOutcomeTimeFrame": [
            "Screening, months 3, 6, 12 and every 12 months thereafter until study conclusion",
            "Screening (only from those subjects who provide consent to participate in PGx sample collection)",
            "Screening, day 10, months 1, 3, 6, and 12"
      ],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Mesoblast, Ltd."
      ],
      "OverallOfficialName": [
            "Fred Grossman, DO"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 3"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "May 29, 2020"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "Time to recurrent non-fatal decompensated heart failure major adverse cardiac events (HF-MACE) that occur prior to the first terminal cardiac event (TCE)."
      ],
      "PrimaryOutcomeTimeFrame": [
            "6 Month minimum"
      ],
      "ReferenceCitation": [
            "Borow KM, Yaroshinsky A, Greenberg B, Perin EC. Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure. Circ Res. 2019 Jul 19;125(3):265-281. doi: 10.1161/CIRCRESAHA.119.314951. Epub 2019 Jul 18. Review. Erratum in: Circ Res. 2019 Aug 16;125(5):e28."
      ],
      "ReferencePMID": [
            "31318648"
      ],
      "ReferenceType": [
            "derived"
      ],
      "RemovedCountry": [
            "Austria",
            "Belarus",
            "Bulgaria",
            "Finland",
            "France",
            "Germany",
            "Italy",
            "Latvia",
            "Lithuania",
            "Netherlands",
            "Poland",
            "Russian Federation",
            "Singapore",
            "Slovenia",
            "Spain",
            "Sweden",
            "Switzerland",
            "United Kingdom"
      ],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "ALT (alanine transaminase), AST (aspartate aminotransferase), GGT (gamma-glutamyl transferase), LDH (lactate dehydrogenase), BUN (blood urea nitrogen), WBCs (white blood cells), ANC (absolute neutrophil count)"
      ],
      "SecondaryOutcomeMeasure": [
            "Time-to-first terminal cardiac event (TCE)",
            "Time-to-hospital admissions for non-fatal decompensated HF events",
            "Time-to-urgent care outpatient HF visits",
            "Time-to-successfully resuscitated cardiac death (RCD) events",
            "Total length of in-hospital stay in intensive care unit for non-fatal decompensated HF events",
            "Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, and successfully RCD events)",
            "Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, successfully RCD events or TCE)",
            "Time-to-cardiac death",
            "Time-to-all-cause death",
            "Time-to-first non-fatal MI (myocardial infarction), non-fatal CVA (cerebrovascular attack) or coronary artery revascularization",
            "Left Ventricular (LV) remodeling in LVESV determined by 2-D echocardiography",
            "Correlations between baseline LVESV <=100 mL and LVESV >100 mL and clinical outcomes",
            "Correlations between baseline LVESV <=100 mL and LVESV >100 mL and change in Month 6 to baseline LVESV and clinical outcomes",
            "LV remodeling in LVEDV determined by 2-D echocardiography",
            "Overall Left Ventricular systolic performance as assessed by left ventricular ejection fraction (LVEF [radionuclide ventriculography {RVG} or echocardiogram])",
            "Functional exercise capacity as assessed by 6 Minute Walk Test",
            "Functional status by New York Heart Association (NYHA) class",
            "Quality of Life Measure - Minnesota Living With Heart Failure (MLHF) questionnaire",
            "Quality of Life Measure - European Quality of Life (EuroQoL) 5-dimensional (EQ-5D) questionnaire",
            "Safety as assessed by occurrence of adverse events related to the index cardiac catheterization on Day 0",
            "Safety as assessed by occurrence of treatment-emergent adverse events",
            "Safety as assessed by clinical laboratory tests (serum chemistry - ALT, AST, alkaline phosphate, GGT, LDH, BUN, creatinine, uric acid, total bilirubin - and hematology - hematocrit, hemoglobin, WBCs, eosinophils, ANC, platelet count)",
            "Safety as assessed by urinalysis (blood, glucose, ketones, total protein)",
            "Safety as assessed by vital signs (pulse, systolic blood pressure [BP], diastolic BP)",
            "Safety as assessed by 12-lead electrocardiogram (ECG) findings - QT interval with Fridericia's correction (QTcF), heart rate-corrected QT interval (QTcB), QT, Q wave, R wave and S wave (QRS) complex, HR and T waves.",
            "Safety as assessed by telemetry monitoring findings (clinically significant arrhythmias)",
            "Safety as assessed by rhythm analysis (specifically, ventricular arrhythmias) by interrogation of any implanted device capable of defibrillation",
            "Safety as assessed by 24-hr Holter monitoring (HR, rate & duration of arrhythmias, a-fib average rate, supra- & ventricular ectopy singles/couplets/runs/totals, sustained & non-sustained ventricular tachycardia, longest pauses RR duration, total pauses)",
            "Safety as assessed by physical examination findings judged as clinically significant changes from baseline by the investigator or newly occurring abnormalities (including weight)",
            "Safety as assessed by important cardiovascular events from adjudicated data"
      ],
      "SecondaryOutcomeTimeFrame": [
            "6 Month minimum",
            "6 Month minimum",
            "6 Month minimum",
            "6 Month minimum",
            "6 Month minimum",
            "6 Month minimum",
            "6 Month minimum",
            "6 Month minimum",
            "6 Month minimum",
            "6 Month minimum",
            "Screening, day 0 (post-procedure), months 3, 6, and 12, and every 12 months thereafter during study conduct (6 Month minimum)",
            "6 Month minimum",
            "6 Month minimum",
            "Screening, day 0 (post-procedure), months 3, 6, and 12, and every 12 months thereafter during study conduct (6 Month minimum)",
            "Screening, day 0 (post-procedure), months 3, 6, and 12, and every 12 months thereafter during study conduct (6 Month minimum)",
            "Screening, months 3, 6, and 12, and every 12 months thereafter during study conduct (6 Month minimum)",
            "Screening, months 3, 6, and 12, and every 12 months thereafter during study conduct (6 Month minimum)",
            "Screening, months 3, 6, and 12, and every 6 months thereafter during study conduct (6 Month minimum)",
            "Screening, months 3, 6, and 12, and every 6 months thereafter during study conduct (6 Month minimum)",
            "Day 0 through discharge from Day 0 hospitalization",
            "Screening through 6 Month minimum",
            "Screening, day 0 (post-procedure), day 10, months 1, 3, 6, and 12, and every 6 months thereafter during study conduct (6 Month minimum)",
            "Screening, day 10, months 1, 3, 6, and 12, and every 6 months thereafter during study conduct (6 Month minimum)",
            "Screening, day 0 (pre and post-procedure), day 1, day 10, months 1, 3, 6, and 12, and every 6 months thereafter during study conduct (6 Month minimum)",
            "Screening, day 0 (pre and post-procedure), day 1, day 10, months 1, 3, 6, and 12, and every 6 months thereafter during study conduct (6 Month minimum)",
            "Day 0 through Day 0 overnight post-procedure",
            "Day 10, months 1, 3, 6, and 12, and every 6 months thereafter during study conduct (6 Month minimum)",
            "Screening, day 0 (post-procedure), day 10, months 1 and 3",
            "Screening, month 12 and every 12 months thereafter until study conclusion (weight measured at screening, day 0 - pre and post-procedure, day 1, day 10, months 1, 3, 6 and 12 and every 6 months thereafter)",
            "6 Month minimum"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "February 14, 2014"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "January 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "January 9, 2014"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "January 8, 2014"
      ],
      "StudyFirstSubmitQCDate": [
            "January 8, 2014"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}